Clinical Scorecard: The Role of Lactylation in Connecting Metabolic Changes and Immune Suppression within the Tumor Microenvironment

At a Glance

Key Highlights

• Lactylation promotes tumor cell malignancy through chromatin accessibility and oncogenic signaling.
• Lactate accumulation in the tumor microenvironment drives immunosuppression.
• Lactylation reprograms immune cells, enhancing M2 macrophage polarization and T cell exhaustion.
• Therapeutic strategies targeting lactylation may reverse immunosuppression and improve treatment outcomes.
• Lactylation represents a novel metabolic-epigenetic-immune paradigm in cancer therapy.

Guideline-Based Recommendations

Diagnosis

• Consider assessing lactylation levels in tumor samples as a biomarker for tumor progression.

Management

• Explore inhibitors of lactate production or lactyltransferases in combination with immune checkpoint inhibitors.

Monitoring & Follow-up

• Monitor immune cell function and lactylation status in the tumor microenvironment during treatment.

Risks

• Potential for lactylation to contribute to immune evasion and therapy resistance.

Patient & Prescribing Data

Patients with various cancers exhibiting metabolic reprogramming

Targeting lactylation may enhance the efficacy of existing cancer therapies.

Clinical Best Practices

• Integrate metabolic profiling with immunological assessments in cancer treatment planning.
• Utilize advanced detection methods for lactylation to inform therapeutic strategies.

Related Resources & Content

• Zhang et al. (2019) in Nature